Laboratoire de Chimie et Biochimie
Pharmacologiques et Toxicologiques (LCBPT)
CNRS UMR 8601
Université Paris Descartes
45 Rue des Saints Pères
75270 Paris Cedex 06
France

Mathieu Rodero

Research Scientist, CNRS

Laboratoire de Chimie et Biochimie pharmacologiques et toxicologiques (LCBPT) – CNRS UMR 8601
Université Paris Descartes
45 Rue des Saints Pères
75270 Paris Cedex 06
France

Since my PhD in 2008, I have been studying immunology in various models of mice and human inflammatory diseases (>70 pubications, 4000 citations. IF : 31 – WOS). In 2019 I was appointed by CNRS in order to foster the development of new therapy and diagnosis tools for inflammatory and auto immune conditions. Our projects, based on a collaborative, multidisciplinary and translational approaches combine access to state of the art technology to material of patients with rare diseases.

Curriculum Vitae

Education
2017: Accreditation to direct research (HDR) at Paris Descartes University (Paris 5), Paris, France
2005 – 2008: PhD in Immunology with honours at the Orsay University (Paris 11), Paris, France
2004 – 2005: Master’s degree in Cell Signaling at the Orsay University (Paris 11), Paris, France
2002 – 2004: Bachelor’s degree in Cellular Biology and Physiology at the Poitiers University, Poitiers, France
2000 – 2002: Superior Laboratory Technician Diploma in Biology and Biotechnology

Research Projects

Pathophysiology of juvenile dermatomyositis.

Juvenile dermatomyositis is a rare auto immune disease of unknown origin characterized by sustained overproduction of type I interferons. We are more specifically interested in the mechanisms responsible for this type I interferon overproduction/signature, and its impact on disease progression and severity. In line with this questioning, we are involved in clinical trials evaluating the benefit of inhibitors of interferon signalling in these patients.

Genotype / phenotype association in genetic auto-inflammatory diseases.

Numerous genes have been associated with inflammatory diseases. Interestingly, mutations in distinct domains of a same protein can be associated with distinct diseases, or variable manifestation of a same disease. We are interested in the molecular and cellular alterations resulting from mutations in different domains of a same protein, and its association with clinical features.

Pathophysiology of adult idiopathic inflammatory and autoimmune diseases.

The pathophysiology of most non-genetic inflammatory and autoimmune diseases is still poorly understood. We aim to identify deregulations of specific pathways within professional immune cells in patients suffering from idiopathic inflammatory or autoimmune diseases. This work should provide new insights into the mechanisms leading to the onset of the diseases and help identify new therapeutic targets or markers that predict the response to treatments

 

Mentoring :

Ph.D :
Thomas RJ Moreau – Since 2021 – Funded by ANR
Margaux Cescato – Since 2021 – Funded by FRM

Master 2:
Samuel Bonhomme (intern 5th year)– 2024- Supported by Année Recherche
Diego Bletry (intern 4th year) – 2024- Supported by  SNFMI
Carine SCHMIDT (intern 4th year) – 2024 – Funded by Societé Francaise de Dermatologie
Yves Jean Zhu (intern 4th year) – 2023 – Supported by Année Recherche and SNFMI-REMI
Francois Maillet (MD) – 2023 – Supported by Année Recherche and GFRS
Antoine Fayand (MD) -2021 – Supported by Année Recherche

Main collaborators:

Dr Brigitte Bader Meunier – Necker Hospital
Dr Benjamin Chaigne – Cochin Hospital
Dr Julien Dairou – UMR8601
Dr Darragh Duffy – Pasteur Institut
Pr Sophie Georgin-Lavialle – Tenon Hospital
Dr Cyril Gitiaux – Necker Hospital
Dr Laurent Le Corre – UMR8601
Dr Isabelle Melki – Robert Debré Hospital
Pr Pierre Quartier – Necker Hospital
Pr Angèle Soria – Tenon Hospital

Last 5 years

Terré et al, Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B-cell-restricted NLRP2 variant. Br J Haematol. 2024

Fayand A*, Cescato M* et al, Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype. J Allergy Clin Immunol. 2023

Fayand A et al, Successful treatment of JAK1 associated inflammatory disease. J Allergy Clin Immunol. 2023

Moreau TRJ, Bondet V, Rodero MP, Duffy D. Heterogeneity and functions of the 13 IFN-α subtypes – lucky for some?. Eur J Immunol. 2023

Hirschenberger M et al, ARF1 prevents aberrant type I interferon induction by regulating STING activation and recycling. Nature Communication, 2023

Bader Meunier B et al, Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody? Rheumatology. 2023

Tan SX et al, pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma. Melanoma Res. 2023

Bekaddour N et al, Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis. Front Immunol 2023

Dabbak I, Rodero MP et al, Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. Rheumatology. 2022

Hamel Y et al, Compromised mitochondrial quality control triggers lipin1-related rhabdomyolysis. Cell Reports medicine. 2021

Rodero MP et al, Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection. J Clin Immunol. 2021

Asano T et al, X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021

Bastard P et al, Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Sci Immunol. 2021

Lepelley A et al, Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A. J Exp Med. 2021

Bondet V, Rodero MP et al, Differential levels of IFNα subtypes in autoimmunity and viral infection. Cytokine, 2021

Voyer TL et al, JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology. 2021

Uggenti C et al, cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet. 2020

Hou C et al, From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies. Arthritis Rheumatol. 2020

De Luca C et al, Expanding the clinical spectrum of Fowler syndrome: Three siblings with survival into adulthood and systematic review of the literature. Clin Genet. 2020

Stefia LV et al, Secretome Components from Faecalibacterium prausnitzii Strains A2-165 and AHMP21 Modulate Cutaneous Wound Inflammation. J Invest Dermatol. 2020

Smith C et al, Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathol. 2020

Williams J et al, Neuromyelitis optica in patients with increased interferon alpha concentrations. Lancet Neurol. 2020

Rice GI et al, Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. Hum Mutat. 2020

 

 

All Publications

Terré et al, Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B-cell-restricted NLRP2 variant. Br J Haematol. 2024

Fayand A*, Cescato M* et al, Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype. J Allergy Clin Immunol. 2023

Fayand A et al, Successful treatment of JAK1 associated inflammatory disease. JACI. 2023

Hirschenberger M et al, ARF1 prevents aberrant type I interferon induction by regulating STING activation and recycling. Nature Communication, 2023

Bader Meunier B et al, Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody? Rheumatology. 2023

Tan SX et al, pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma. Melanoma Res. 2023

Bekaddour N et al, Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis. Front Immunol 2023

Dabbak I, Rodero MP et al, Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. Rheumatology 2022

Hamel Y et al, Compromised mitochondrial quality control triggers lipin1-related rhabdomyolysis. Cell Reports medicine. 2021

Rodero MP et al, Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection. J Clin Immunol. 2021

Asano T et al, X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021

Bastard P et al, Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Sci Immunol. 2021

Lepelley A et al, Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A. J Exp Med. 2021

Bondet V et al, Differential levels of IFNα subtypes in autoimmunity and viral infection. Cytokine, 2021

Voyer TL et al, JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology, 2021

Uggenti C et al, cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet 2020

Hou C et al, From diagnosis to prognosis: Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies. Arthritis Rheumatol, 2020

De Luca C et al, Expanding the clinical spectrum of Fowler syndrome: Three siblings with survival into adulthood and systematic review of the literature. Clin Genet. 2020

Stefia LV et al, Secretome Components from Faecalibacterium prausnitzii Strains A2-165 and AHMP21 Modulate Cutaneous Wound Inflammation. J Invest Dermatol. 2020

Smith C et al, Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathol. 2020

Williams J et al, Neuromyelitis optica in patients with increased interferon alpha concentrations. Lancet Neurol. 2020

Rice GI et al, Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. Hum Mutat. 2020

Gitiauc C, […], Bader Meunier B* and Rodero MP* ,Inhibition of IFNa secretion in cells from patients with JDM under TBK1 treatment revealed by Single Molecular Assay technology . Rheumatology, 2019

Melki I et al, Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology 2019

Van Eyck L et al, Biallelic mutations in MTPAP associated with a lethal encephalopathy. Neuropediatrics 2019.

Melki I, […],  Rodero MP* and Bader Meunier B*. Circulating interferon-α measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity. Arthritis Rheumatol, 2019

Smith N, Rodero MP et al. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment.. ScienceAdvences, 2019.

Gratia M, Rodero MP et al. Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS.. J Exp Med, 2019.

Rice GI et al. Reverse Transcriptase Inhibitors in Aicardi-Goutières Syndrome.. N Engl J Med, 2018.

Hernandez N, et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency.. J Exp Med, 2018.

Ruaud L, Rice GI, Cabrol C, Piard J, Rodero MP et al. Autosomal dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. Human Mutation, 2018.

Ladislau L et al. Jak inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018.

Llibre A, Bondet V, Rodero MP et al. Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-Linked Immunosorbent Assay for Human Interferon-α. Jove 2018.

Rodero MP et al. Type I interferon mediated autoinflammation due to DNase II deficiency. Nat Commun 2017.

Lee J, Rodero MP et al. Interleukin-23 regulates interleukin-17 expression in wounds, and its inhibition accelerates diabetic wound healing through the alteration of macrophage polarization. FASEB J 2017.

Gitiaux C, et al. Myogenic progenitor cells exhibit IFN type I-driven pro-angiogenic properties and molecular signature during juvenile dermatomyositis. Arthritis Rheumatol, 2017.

Fremond ML*, Uggenti, C*, […], Rodero MP. TBK1 / IKKE blockade inhibits mutant STING mediated inflammatory response in patient cells. Arthritis Rheumatol, 2017.

Rodero MP* et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med, 2017.

Amsellem V, Abid S, Poupel L, Parpaleix A, Rodero MP* et al. Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension Am J Respir Cell Mol Biol, 2017.

Melki I, Rose Y, […], Rodero MP* Crow YJ*.  Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J Allergy Clin Immunol, 2017.

Rice GI, Melki I, Frémond ML, Briggs TA, Rodero MP et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. J Clin Immunol, 2017.

Patel J, Seppanen EJ, Rodero MP et al Functional Definition of Progenitors Versus Mature Endothelial Cells Reveals Key SoxF-Dependent Differentiation Process. CIRCULATION, 2017.

Rodero MP et al, JAK inhibition in STING-associated interferonopathy. ARD, 2016.

Fremond ML*, Rodero MP* et al,          Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol 2016.

Jenkinson EM, Rodero MP et al, Mutations in SNORD118 cause cerebral microangiopathy leukoencephalopathy with calcifications and cysts. Nature Genetics 2016.

Uettwiller F, Sarrabay G, Rodero MP et al, ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open, 2016.

Rowe CJ, Tang F, Hughes MC, Rodero MP et al, Molecular markers to complement sentinel node status in predicting survival in patients with high risk locally invasive melanoma. Int J Cancer. 2016.

Lee J ;Seppanen E, Patel J, Rodero MP and Khosrotehrani K, ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis. Exp Dermatol. 2015.

Rodero MP* et al : Immune surveillance of the lung by migrating tissue-monocytes. eLIFE. 2015.

Y. Handoko, Rodero MP et al. Lack of Evidence From a Transgenic Mouse Model that the Activation and Migration of Melanocytes to the Epidermis after Neonatal UVR Enhances Melanoma Development. J. Invest. Dermathol, 2015 Jun .

Hamond P, Rodero MP et al. Tracking mouse bone marrow monocytes in vivo. JOVE, 2015 Feb 27;(96):e52476

Rodero MP et al, In vivo imaging reveals a pioneer wave of monocyte recruitment into mouse skin wounds. Plos one, 2014 Oct.

Rodero MP*, H. Y. Handoko* et al. Differential effects of ultraviolet irradiation in neonatal versus adult mice are not explained by defective macrophage or neutrophil infiltration. J. Invest. Dermathol, 2014 Jul.

Rodero MP et al. Control of Both Myeloid Cell Infiltration and Angiogenesis by CCR1 Promotes Liver Cancer Metastasis Development in Mice. Neoplasia, 2013 Jun.

  1. Y. Handoko*, Rodero MP* et al. UVB-induced melanocyte proliferation in neonatal mice driven by CCR2-independent recruitment of Ly6c(low)MHCII(hi) macrophages. J. Invest. Dermathol, 2013 Jul;

Rodero MP et al, Wound-associated macrophages control collagen 1α2 transcription during the early stages of skin wound healing. Exp Dermatol. 2013 Feb;22.

Rodero MP et al. Reduced Il17a expression distinguishes a Ly6clow MHCIIhi macrophage population promoting wound healing. J. Invest. Dermathol, 2013 Mar.

Rodero MP et al. Increase lymphangiogenesis in melanoma during pregnancy: correlation with the prolactin signalling pathway Journal of the European Academy of Dermatology and Venereology 2012 May 2

Ramos MV, Auvynet C, Poupel L, Rodero M et al Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome. Am J Pathol 2012.

Cochain C*, Rodero MP* et al. Regulation of monocyte subsets systemic levels by distinct chemokine receptors controls postischemic neovascularization. Cardiovasc Res 2010 Oct 1.

El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, Laigle-Donadey F, Rodero M et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 2009.

Dorgham K, Ghadiri A, Hermand P, Rodero M et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009.

Rodero M et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 2008.

Raoul W, Keller N, Rodero M et al. Role of the chemokine receptor CX3CR1 in the mobilization of phagocytic retinal microglial cells. J Neuroimmunol 2008.

Guedj M, Bourillon A, Combadieres C, Rodero M et al. Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat 2008.

Combadiere C, Potteaux S, Rodero M et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008

Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Criniere E, Rodero M et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet, 2008.

El Hallani S, Marie Y, Idbaih A, Rodero M et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neurooncol 2007.

Combadiere C, Feumi C, Raoul W, Keller N, Rodero M et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007.

Rodero M, et al. Melanoma susceptibility and progression: Association study between polymorphisms of the chemokine (CCL2) and chemokine receptors (CX3CR1, CCR5). J Dermatol Sci 2007.

Nadif R, Mintz M, Rivas-Fuentes S, Jedlicka A, Lavergne E, Rodero M et al. Polymorphisms in chemokine and chemokine receptor genes and the development of coal workers’ pneumoconiosis. Cytokine 2006.

Reviews, comments and book chapter:

Moreau TRJ, Bondet V, Rodero MP, Duffy D. Heterogeneity and functions of the 13 IFN-α subtypes – lucky for some?. Eur J Immunol. 2023

Gies  V et al. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. Frontieres Immunology. 2020

Loyher PL, Rodero MP et al. Role of Chemokines and Chemokine Receptors in Cancer, Cancer Immunology, Springer, 2020.

Della-mina E, Rodero MP and Crow YJ: Polymorphisms in IFIH1 – the good and the bad. Nat Immunol. 2017

Rodero MP and Crow YJ: Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. JExpMed 2016

Rodero MP and Crow YJ: cGMP-AMP synthase paves the way to autoimmunity. PNAS 2015

Rice GI, Rodero MP, Crow YJ: Human disease phenotypes associated with mutations in TREX1. J Clin Immunol. 2015.

Rodero MP et al. Role of chemokines and chemokine receptors in cancers. Cancer Immunology: Translational Medicine from Bench to Bedside, Springer, 2014.

Rodero MP and Khosrotehrani K. Skin wound healing modulation by macrophages. IJCEP 2010

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.